Brind.
  1. IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.
  2. IDEXX customers are shifting pancreatic lipase testing to the Catalyst instrument platform.
  3. Higher revenue drove increased profit margin for IDEXX Laboratories, Inc. on August 5, 2025.
  4. FMT and HST contributed $310.9 million and $365.3 million, respectively, to Idex's net sales on July 30, 2025.

Growth in the Health & Science Technologies segment drove Q2 results for IDEX, which provides high-purity gas filtration products.

1 report, 1 independent Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Growth in the Health & Science Technologies segment drove Q2 results for IDEX, which provides high-purity gas filtration products.

Keep exploring

Part of

FMT and HST contributed $310.9 million and $365.3 million, respectively, to Idex's net sales on July 30, 2025. All 1 developments

Within IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.

Coverage

Newest first; wire copies grouped